Cargando…
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an enormous challenge to the medical system, especially the lack of safe and effective COVID-19 treatment methods, forcing people to look for drugs that may have therapeutic effects as...
Autores principales: | Zequn, Zheng, Yujia, Wu, Dingding, Qian, Jiangfang, Lian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746509/ https://www.ncbi.nlm.nih.gov/pubmed/33345848 http://dx.doi.org/10.1016/j.ejphar.2020.173813 |
Ejemplares similares
-
Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19
por: Echarte-Morales, Julio, et al.
Publicado: (2021) -
Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Complete atrioventricular-block, torsades-de-pointes and QT-interval-prolongation following off label use: 2 case reports
Publicado: (2020) -
COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels
por: Szendrey, Mark, et al.
Publicado: (2021) -
QT interval prolongation with hydroxychloroquine plus azithromycin
Publicado: (2020) -
Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
por: Russo, Vincenzo, et al.
Publicado: (2020)